In the last trading session, 35.85 million shares of the Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) were traded, and its beta was 2.04. Most recently the company’s share price was $0.24, and it changed around $0.0 or 1.44% from the last close, which brings the market valuation of the company to $44.65M. TNXP currently trades at a discount to its 52-week high of $12.48, offering almost -5100.0% off that amount. The share price’s 52-week low was $0.12, which indicates that the current value has risen by an impressive 50.0% since then. We note from Tonix Pharmaceuticals Holding Corp’s average daily trading volume that its 10-day average is 65.55 million shares, with the 3-month average coming to 106.32 million.
Tonix Pharmaceuticals Holding Corp stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended TNXP as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Tonix Pharmaceuticals Holding Corp is expected to report earnings per share of -7.68 for the current quarter.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) trade information
Instantly TNXP has showed a green trend with a performance of 1.44% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.2600 on recent trading dayincreased the stock’s daily price by 7.69%. The company’s shares are currently down -27.56% year-to-date, but still down -6.83% over the last five days. On the other hand, Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is -28.45% down in the 30-day period. We can see from the shorts that 7.67 million shares have been sold at a short interest cover period of 0.35 day(s).
Tonix Pharmaceuticals Holding Corp (TNXP) estimates and forecasts
Tonix Pharmaceuticals Holding Corp share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -57.35 percent over the past six months and at a 91.94% annual growth rate that is well above the industry average of 16.50%. The year-over-year growth rate is expected to be 64.78%, up from the previous year.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of 3.2M in revenue for the current quarter. 2 analysts expect Tonix Pharmaceuticals Holding Corp to make 4.1M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 3.78M and 2.48M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -15.32%. Forecasts for the next quarter put sales growth at 65.19%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 79.31%.
TNXP Dividends
Tonix Pharmaceuticals Holding Corp’s next quarterly earnings report is expected to be released in February.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.17% of Tonix Pharmaceuticals Holding Corp shares, and 0.23% of them are in the hands of institutional investors. The stock currently has a share float of 0.23%.
Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Nov 30, 2024 . The former held 112.39 shares worth $26850.0, making up 0.06% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 7.3 shares worth around $1743.0, which represents about 0.00% of the total shares outstanding.
